RxDoctor Payments Data

Dennis Lang, DO

Cardiovascular Disease · Sumter, SCNPI 1730307463

Payments from drug & device makers

$8,394in general payments, 2019–2025

Across 502 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$1K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$1K
  • Amgen$981
  • Alnylam Pharmaceuticals Inc.$586
  • Merck$545
  • Pfizer$459
  • plus $3K from 25 others

What the payments were for

  • Food & beverage$8,394100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$8,394 in reported general payments places this provider in the 65th percentile of 257 cardiovascular disease providers in South Carolina.

See all cardiovascular disease providers in South Carolina

Medicare billing

Part B allowed, 2024
$606,918
Medicare patients
2,098
Services billed
7,964

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan592$594,348
EliquisApixaban691$588,358
XareltoRivaroxaban254$224,989
JardianceEmpagliflozin255$215,426
MultaqDronedarone Hcl132$160,257
Repatha SureclickEvolocumab200$153,130
FarxigaDapagliflozin Propanediol83$62,918
BrilintaTicagrelor22$17,597
Dofetilide76$12,051
Metoprolol Succinate619$9,321
Rosuvastatin Calcium423$8,281
Amlodipine-ValsartanAmlodipine Besylate/Valsartan84$7,040
Pitavastatin Calcium14$4,792
Ranolazine ErRanolazine46$4,535
Amiodarone Hcl151$4,487

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$1,462$594,348592 claims
PfizerEliquis$459$588,358691 claims
Johnson & JohnsonXarelto$276$224,989254 claims
Boehringer IngelheimJardiance$441$215,426255 claims
Sanofi-aventis U.S. LLCMultaq$373$160,257132 claims
AstraZenecaFarxiga, Brilinta$431$80,515105 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 257 cardiovascular disease providers in South Carolina.

Other cardiovascular disease in Sumter

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →